DRUGS OF TODAY

计划和组织《今日药物》是一份同行评议的期刊，在科学出版物市场上享有40多年的声誉。它是关于药物进入国际市场的宝贵资料来源。其最新的专著和文章，使医学界的最新发展，在诊断和治疗跨治疗领域。本期刊包括以下部分:通过对文献和制药公司提供的信息的严格审查，由领先专家编写的关于最近批准和推出的药物的专著和最新评论。此外，亦会公布最新的有关资料或已上市药物的最新资料(例如新配方、新适应症等)。综述文章，重点介绍人类疾病诊断和治疗的最新进展，以及用于诊断疾病、监测治疗反应、预测毒性和确定靶向治疗候选药物的生物标志物。会议报告，会议报告提供的重点从世界各地的主要大会和研讨会。选择要审查的主题编辑委员会由各自领域的主要权威人士组成，他们被挑选出来，以确保涵盖广泛的治疗领域。执行局成员建议由其领域内的当局进行审查，以确保全面涵盖所有主题，并强调所有当前重要的问题。提交的文章在发表前要经过同行评审。定期出版关于最近销售的药品和专题讨论会论文集的补充问题。补编是由领先的专家根据当前的科学文献和他们自己的经验编写的。p-ISSN: 1699-3993, e-ISSN: 1699-4019 (B-47252-2009)成立:1965出版:12期/年和补编读者简介:医学专家，临床医生，市场营销和企业战略总监，药剂师和药理学家

AIMS & ORGANIZATIONDrugs of Today is a peer-reviewed journal with a solid reputation of over 40 years in the scientific publications market. It is a valuable source of information on drugs introduced into the international market. Its updated monographs and articles keep the medical community abreast of the latest developments in diagnosis and treatment across therapeutic areas. This journal includes the following sections:Monographs, up-to-date reviews on recently approved and launched drugs prepared by leading specialists after a rigorous review of the literature and from information provided by pharmaceutical companies. Updates with new relevant information or on line extensions of marketed drugs (e.g., novel formulations, new indications, etc.) are also published.Review articles, highlighting the latest developments in the diagnosis and treatment of human diseases, as well as biomarkers for diagnosing diseases, monitoring treatment response, predicting toxicity and identifying candidates for targeted therapy.Meeting reports, conference reports providing highlights from key congresses and symposia around the world.SELECTION OF TOPICS TO BE REVIEWEDThe Editorial Board comprises major authorities in their field who are selected to ensure that a wide variety of therapeutic areas are covered. The Board members recommend reviews from authorities within their field to guarantee that all topics are covered comprehensively and that all issues of current importance are emphasized. Submitted articles are peer reviewed before publication.Supplementary issues devoted to recently marketed drugs and symposia proceedings are periodically published. Supplements are written by leading specialists on the basis of current scientific literature and their own experience. p-ISSN: 1699-3993, e-ISSN: 1699-4019 (B-47252-2009) Established: 1965 Published: 12 issues/year and supplements Reader profile: Medical specialists, clinicians, marketing & corporate strategy directors, pharmacists & pharmacologists